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Background
Transfusion of red blood cells (RBC) is the only clini-
cally effective therapeutic approach for treating oxygen
transport deficits (i.e. blood loss in surgical interventions
and anaemia). However potential shortage of transfusa-
ble RBC has been predicted for the near future as a
result of an imbalance between supply and demand due
to aging population, an increase in the transmission of
infectious diseases, limited compatibility of stored
stocks, and the requirement for rare blood groups [1,2].
This situation has a direct impact in Public Health and
it has consequently spurred the development of novel
technologies for the generation of blood substitutes. The
candidate products for human use should be safe, dis-
play adequate profiles for the uptake, transport and
delivery of oxygen, a prolonged half-life in the blood-
stream, stability at room temperature that would facili-
tate cost-effective storage, and they must be obtained
under Good Manufacturing Practice (GMP) quality
standards. In vitro production of RBCs [3-5] from
hematopoietic stem/progenitor cells (HSC) [6,7],
embryonic stem (ES) cells [8], or induced pluripotent
stem (iPS) cells [9] under controlled culture conditions
offers a potential solution to overcome this medical and
social issue. However mass production of RBC has not
been attained yet. The attractiveness of developing bio-
processes for ex vivo production of RBC also resides in
the fact that enucleated cells pose no risk of tumorigeni-
city (no matter whether RBC are derived from immorta-
lized or pluri-/multipotent cells) and, therefore, they can
be transfused without hazard into the recipient. Enu-
cleated RBCs can be selected by size (e.g., by filtration),
and impurities of nucleated cells can be eliminated by
irradiation without affecting the structure and function
of RBCs. Indeed, such irradiation is routinely used
before transfusion in order to eliminate any remaining
lymphocytes. Besides, transplantation of progenitor cells
requires compatibility for major histocompatibility anti-
gens [14], but this is not the case for enucleated RBCs,
which only require the compatibility of ABO and RhD
blood phenotypes.
Given the potential of stem cells to recapitulate ery-
thropoiesis in vitro under controlled conditions in stan-
dard T-flask cultures, we transferred such methodology
into stirred tank bioreactors, as the first step towards
scaling the bioprocess up to the production of clinically
relevant doses. Furthermore, we compared the charac-
teristics of the cells produced in bioreactors to those
obtained from traditional manual cultures.
Materials and methods
The expansion strategy lasted 21 days and consisted of
3 stages based on the use of different media additives:
1) isolation of CD34+ cells from a fresh umbilical cord
blood (CB) unit using magnetic beads (on day 0);
2) expansion of CD45+ progenitors up to day 7, using
3 IU/mL Erythropoietin (EPO, Amgen), 100 IU/mL
Stem Cell Factor (SCF, Amgen), 5 ng/mL Interleukin-3
(IL-3, CellGenix), 10 µM hydrocortisone (HC, Nyoden),
330 µg/mL transferrin (Life Technologies), 10 µg/mL
insulin (Life technologies), 2 mM L-glutamine (Life
Technologies), 5% v/v human serum B (hSerB, Banc de
Sang i Teixits)-supplemented IMDM (Lonza) medium,
and 3) the subsequent maturation and enucleation of ery-
throblasts into erythrocytes (CD45-, CD36-, CD235+ and
CD71-) using EPO/SCF/transferrin/insulin/L-glutamine/
hSerB-supplemented media. Cell culture concentration
was adjusted at 5x105 cells/mL every 2 days and† Contributed equally
Divisió de Teràpies Avançades/XCELIA, Banc de Sang i Teixits, Barcelona,
Spain
Caminal et al. BMC Proceedings 2015, 9(Suppl 9):P67
http://www.biomedcentral.com/1753-6561/9/S9/P67
© 2015 Caminal et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
maintained at 37ºC either in humidified 5% CO2 incuba-
tors or in stirred tank bioreactors (Applikon) at 90 rpm.
Cells were analyzed by flow cytometry at different cul-
ture times for phenotypic expression of specific surface
markers using a FACSCalibur flow cytometer (Becton
Dickinson). May-Grünwald-Giemsa stainings were
performed to identify enucleated cells by microscopy.
Erythrocytes were quantified by the Retic-Count assay
(Becton Dickinson). Glucose and lactate concentrations
in supernatants were determined using an YSI 2700
SELECT automated analyser (Yellow Springs Instru-
ments), as described elsewhere [10]. Haemoglobin (Hb)
content was determined by High Performance Liquid
Chromatography (HPLC).
Figure 1 Production strategies for the production of red blood cells in stirred tank bioreactors and T-flasks. A. Schematic representation
of the expansion strategy. B. Growth profiles and metabolic parameters in bioreactor and manual cultures. C. Characterisation of cellular
products resulting from bioreactor and manual cultures. D. Characterisation of haemoglobin content (Hb) in erythrocytes produced ex vivo, after
filtration. Part of the figure was used from ‘’Medical Art Gallery’’ (Les Laboratoires Servier).
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Results and discussion
Considerable progress has been made in the recent years
with regard to biological control of the expansion and
maturation of erythroid cells with the objective of gener-
ating enucleated RBC ex vivo [11]. Giarratana et al.
managed to generate large amounts of RBC in vitro
from CD34+ HSC isolated from CB [12]. However, that
procedure presented some limitations for its translation
to the clinical setting, such as low yields and the
requirement of co-culture with murine or human stro-
mal cells. In order to overcome these issues, we devel-
oped a culture strategy that emulates erythropoieis ex
vivo, also using CD34+ HSC isolated from CB as start-
ing material, which enabled the production of enu-
cleated erythrocytes in the absence of feeder cells. The
resulting haemoglobin was composed of fetal (53 ± 12%,
n = 2) and adult (26 ± 8%, n = 2) isoforms, very similar
to that found in neonatal peripheral blood (72% of fetal
Hb and 23% of adult Hb). The potential clinical use of
this product is supported by the fact that patients suffer-
ing from inherited persistence of fetal Hb do not
develop anaemia [7,13]. Both bioreactor and manual cell
culture strategies displayed a similar behaviour charac-
terised by high cellular expansion during phase 2, which
was maintained during phase 3 (where maturation
occurred) and high viability rates, in the range 60-90%.
Glucose consumption and lactate generation showed
similar profiles in both culture strategies (Figure 1).
During erythroid progenitor differentiation, CD45
expression decreased while CD36 expression appeared
gradually along the culture time to eventually disappear
in mature erythrocytes. The two most mature popula-
tions (CD36+CD45- and CD36-CD45-) were analysed for
CD71 and CD235a expression at the end of the cultures.
High levels of CD71 and CD235a are indicative of the
reticulocyte phenotype, while the expression of CD71 is
lost in mature erythrocytes. In terms of its clinical use,
this does not pose a problem, since it has been demon-
strated that reticulocytes fully mature into erythrocytes,
once they are injected into the bloodstream [2,6].
Bioreactor expansion favoured culture maturation, as the
percentages of most mature populations were higher.
Presence of enucleated cells were confirmed in both
culture strategies by May-Grünwald-Giemsa staining.
Nucleated cells were removed from the final product by
filtering and the final product was composed of a pure
population of biconcave in vitro-produced erythrocytes
(Figure 1).
Kinetic parameters summarized in Table 1 evidenced
that the enucleated cell yield per each initially seeded
CD34+ cell was higher (3.2x104) in manual cultures
than in bioreactors (1.34x104). However, percentages of
enucleation were larger in bioreactors (67.50% in front
of 44.20% in manual culture). This seems to indicate
that erythroid progenitors mature faster in bioreactors,
losing some of their expansion capacity, as a conse-
quence. Concerning the use of bioreactors for erythro-
cytes culture a limited number of publications is
available. Giarratana and collaborators reviewed some of
them but it is very difficult to compare the results
obtained, as a wide range of bioreactors have been
tested [5].
Existing cell culture technologies for RBC production
are not easily transferable to large-scale settings and,
moreover, cell yields using CB as starting material are
far behind those needed in the clinical setting. Hence, it
is not likely that the first attempts to generate massive
quantities of ex vivo cultured erythrocytes will use this
stem cell source. Instead, much work is currently
invested on either establishing cell lines or using human
embryonic stem cells (hES) and induced pluripotent
stem cells (iPS), as unlimited source of HSCs [5].
Conclusions
We demonstrated the feasibility to obtain red blood
cells ex vivo from CD34+ umbilical cord blood cells
and transfer the expansion strategy from manual cul-
tures to stirred tank bioreactors. Phenotypic characteri-
sation and enucleation rates were similar in manual and
bioreactor strategies. Although cells cultured in bioreac-
tors showed lower expansion potential, higher matura-
tion yields were observed. Further work will focus on
bioprocess optimisation and scale up to clinically signifi-
cant doses.
Table 1. Summary of kinetic parameters
MANUAL CULTURE BIOREACTOR CULTURE
Enucleation percentage 44.20% 67.50%
Initial CD34+ cell number 2x105 5x105
Total Expansion Factor 7.27x104 1.99x104
Theoretical number of total cells 1.45x1010 9.95x109
Theoretical number of total enucleated cells 6.41x109 6.72x109
Theoretical number of enucleated cells per CD34+ 3.2x104 1.34x104
Results at day 21, from one out of 3 independent experiments. Theoretical values indicate the predicted values if media volumes were increased instead of fixed
at 250 mL.
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